A Phase 1 interventional study of LDE225 and Wafarin in Advanced Solid Tumor, sponsored by Novartis Pharmaceuticals. Completed at 13 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-12-19.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a multi center, open-label study to evaluate the drug-drug interaction of LDE225 on the PK of bupropion and warfarin patients with advanced solid tumors. Subjects will receive 800mg daily of LDE225 and two separate doses of either bupropion or warfarin.
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
At least 15 evaluable patients with advanced solid tumors will be enrolled into the study into the warfarin group.
Drug: LDE225 · Drug: Wafarin
At least 15 evaluable patients with advanced solid tumors will be enrolled into the study into the Bupropion group
Drug: LDE225 · Drug: Bupropion
LDE225 800 mg once daily dosing will begin on Cycle 1 Day 1 of a 28-day cycle.Treatment with LDE225 for both groups will continue until the patient experiences unacceptable toxicity that precludes further treatment, disease progression, withdrawal of consent and/or at the discretion of the investigator.
15 mg single dose of warfarin (oral tablet) will be given to patients.
75 mg single dose of bupropion(oral tablet, from an immediate release formulation) will be given to patients
Pharmacokinetics (PK) parameter AUClast for S- and R-warfarin
Pharmacokinetics of warfarin : Maximum observed plasma concentration after drug administration
Time frame: 7 days
PK parameter AUClast for bupropion
Pharmacokinetics bupropion : Maximum observed plasma concentration after drug administration
Time frame: 7 days
PK parameter AUCinf for bupropion
Pharmacokinetics of bupropion : Maximum observed plasma concentration after drug administration
Time frame: 7 days
PK parameter AUCinf for S- and R-warfarin
Pharmacokinetics of warfarin and bupropion : Maximum observed plasma concentration after drug administration
Time frame: 7 days
PK parameter Cmax for S- and R-warfarin
Pharmacokinetics of warfarin : Maximum observed plasma concentration after drug administration
Time frame: 7 days
PK parameters Cmax for bupropion
Pharmacokinetics of Bupropion : Maximum observed plasma concentration after drug administration
Time frame: 7 days
effects of LDE225 on the pharmacodynamic activity of warfarin
INR parameter (International Normalized Ratio) will be assessed to evaluate the pharmacodynamic effect of warfarin.
Time frame: 7 days
safety of LDE225 when administered alone and concomitantly with either bupropion or warfarin
safety laboratory parameters, adverse event reports, changes in vital signs, changes in physical examination parameters
Time frame: 28 days cycles
evaluate the preliminary evidence of anti-tumor activity of LDE225 in patients with advanced solid tumors
CT or MRI imaging parameters to determine the objective response rate according to RECIST 1.1 (Response Evaluation Criteria In Solid Tumors)
Time frame: every other cycle
assess the effect of LDE225 treatment on cardiac function
ECGs will be performed to determine the effect of LDE on the cardiac function.
Time frame: screening, cycle 4 and EOT
effects of LDE225 on the pharmacodynamic activity of warfarin
PT (Prothrombin time) parameter will be assessed to evaluate the pharmacodynamic effect of warfarin.
Time frame: 7 days
safety of LDE225 when administered alone and concomitantly with either bupropion or warfarin
safety laboratory parameters
Time frame: 28 days cycles
safety of LDE225 when administered alone and concomitantly with either bupropion or warfarin
adverse event reports
Time frame: 28 days cycles
safety of LDE225 when administered alone and concomitantly with either bupropion or warfarin
changes in vital signs
Time frame: 28 days cycles
The record gives a start of Apr 2013, a primary completion of Aug 2016 and a completion of Aug 2016. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sonidegib